NCT00483093 - Study of NGR-hTNF in Combination With Cisplatin in Solid Tumor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

June 30, 2010

Study Completion Date

April 30, 2013

Conditions

Solid Tumors

Interventions

DRUG

NGR-hTNF

iv q3W escalating dose NGR-hTNF up to 1.6 mcg/sqm

DRUG

Cisplatin

iv q3W 80 mg/sqm 30 minutes after NGR-hTNF infusion for a maximum of six cycles

Trial Locations (2)

Fondazione San Raffaele del Monte Tabor, Milan

Istituto Europeo Oncologico, Milan